All News
Filter News
Found 809,068 articles
-
McKesson Corporation Fiscal 2019 Third Quarter Conference Call Scheduled for January 31, 2019
1/7/2019
McKesson Corporation will release financial results for its third fiscal quarter ended
-
Poxel Announces Presentation of PXL065 Data at the 2019 NASH-TAG Conference
1/7/2019
Presentation highlighted different stereoisomer properties of pioglitazone and other thiazolidinediones (TZDs)
-
JANSSEN SUBMITS APPLICATION TO EUROPEAN MEDICINES AGENCY SEEKING APPROVAL OF STELARA® (USTEKINUMAB) FOR TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
1/7/2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Group Type II Variation Application to the European Medicines Agency (EMA) seeking approval of STELARA® (ustekinumab) for the treatment of adults withmoderately to severely active ulcerative colitis (UC).
-
McCann Health Named among Top 10 'Best Places to Work' by Ad Age
1/7/2019
McCann Health today was named to Ad Age's 2019 "Best Places to Work" list, ranking ninth among all North American ad agencies, ad tech firms, media companies and marketing companies with more than 200 employees
-
Theravance Biopharma Announces Alignment of Workforce with Focus on Key Strategic Priorities
1/7/2019
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced a reduction in workforce to align with its focus on continued execution of key strategic programs, and advancement of selected late-stage research programs toward clinical development
-
Safeguard Scientifics Partner Company Propeller Health Acquired By ResMed
1/7/2019
Safeguard to realize $41.4 million in cash proceeds, representing an approximate 3x cash-on-cash return and 34% IRR
-
QIAGEN Launches QIAcube Connect – Next-Generation Automation for Sample Processing in Research Labs
1/7/2019
Enabling labs to efficiently process increasingly complex samples with over 3,000 proven protocols, advanced digital capabilities and connectivity
-
Nanobiotix and MD Anderson Cancer Center announce a large-scale, comprehensive clinical collaboration on NBTXR3
1/7/2019
NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205) and The University of Texas MD Anderson Cancer Center today announced a large-scale, comprehensive clinical research collaboration to evaluate innovative strategies for treating patients with head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers.
-
ENA Partners With Filmmaker Carolyn Jones On Emergency Nursing Documentary
1/7/2019
The Emergency Nurses Association on Monday proudly announced a partnership with renowned filmmaking team Carolyn Jones Productions on a documentary project which celebrates emergency nurses and the impact they have on patients across the country.
-
Philips Cares digitizes the aging and caregiving experience
1/7/2019
At CES 2019 (Booth #44219, January 8-11, Las Vegas, NV), Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today launched Philips Cares in the U.S. to help family caregivers be there for their aging loved ones, easing and enriching their aging journey by leveraging digital technology.
-
Medidata Appoints Industry Leader Sastry Chilukuri as Executive Vice President of Digital and AI Solutions
1/7/2019
Medidata today announced the addition of executive vice president of Digital and AI Solutions, Sastry Chilukuri to its senior leadership team.
-
QIAGEN Unveils Plans for Next-Generation Digital PCR Systems
1/7/2019
Preparing for 2020 launch of novel digital PCR systems with fully integrated workflow and menu of QIAGEN assays, advantages of improved multiplexing, throughput and scalability
-
QIAGEN to Develop QuantiFERON®-TB Access as a New Test for Low-Resource, High-Burden Regions in Global Fight Against TB
1/7/2019
Adapting the power of QuantiFERON®-TB technology to advance global TB control efforts in new partnership with Ellume
-
Modus Therapeutics Completes Enrollment of its Randomized, Placebo-Controlled Phase II Clinical Trial Evaluating Sevuparin for the Management of Acute Vaso-Occlusive Crisis (VOC) in Patients with Sickle Cell Disease
1/7/2019
Modus Therapeutics AB, a company developing innovative treatments in high unmet medical need disease areas with a focus on sickle cell disease (SCD), announces that it has completed patient enrollment in its Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Sevuparin Infusion for the Management of Acute
-
BioMarin Highlights Key Milestones for 2019 at 37th Annual J.P. Morgan Healthcare Conference in San Francisco
1/7/2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a company focused on innovative therapies to treat rare diseases, provided highlights to the investment community on its key milestones for 2019 at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco.
-
The Vitamin Shoppe® Announces New Chief Technology Officer
1/7/2019
Vitamin Shoppe, Inc. (NYSE: VSI) an omni-channel, specialty retailer of nutritional products, today announced that Andrew Laudato has joined The Vitamin Shoppe as Executive Vice President, Chief Technology Officer effective immediately
-
QIAGEN Acquires N-of-One, Expanding Its Clinical Bioinformatics Capabilities in Molecular Oncology Decision Support
1/7/2019
Enhancing QIAGEN’s industry-leading position with access to MarkerMine™ database and real-world evidence insights that provide insights for targeted therapy options
-
MGI Announces Milestone of 1,000 Sequencers Installed and Opens Early Access Program for Groundbreaking Ultra-High-Throughput Sequencer, MGISEQ-T7
1/7/2019
MGI, established in 2016 as a subsidiary of global genomics leader BGI Group, announced it has reached a new milestone of 1,000 MGI sequencers installed in 16 countries.
-
Foundation Medicine Announces Executive Leadership Transition
1/7/2019
Foundation Medicine, Inc. today announced the appointment of Cindy Perettie as chief executive officer, effective February 4, 2019. Ms. Perettie will succeed Troy Cox.
-
PrimeVax Immuno-Oncology Receives IND Permission From FDA
1/7/2019
PrimeVax Immuno-Oncology, Inc. announced today that the company has successfully received their Investigational New Drug (IND) Application permission from the FDA to begin running their first human clinical trial